Chi Van Dang

Last updated
Chi Van Dang Chi Van Dang.jpg
Chi Van Dang

Chi Van Dang is a hematological oncologist and researcher, currently serving as the Scientific Director of Ludwig Institute for Cancer Research. [1] He is known for his research on genetics, the MYC gene and the cellular energy metabolism of cancer.

Contents

Dang has served as president of the American Society for Clinical Investigation. [2] He has been elected to the National Academy of Medicine, [2] the American Association for Cancer Research, [3] the American Academy of Arts and Sciences, [4] the American Society for Clinical Investigation, [2] and the Association of American Physicians, [5] among others.

Early life and academics

Chi Van Dang was born in Saigon, Vietnam [6] as one of ten children. [7] Dang's father was Chieu Van Dang, Vietnam's first neurosurgeon and was once the dean of the University of Saigon School of Medicine. [1] [7]

After arriving in the United States in 1967, Dang completed his B.S. degree in Chemistry at the University of Michigan in 1975, [2] his Ph.D in chemistry at Georgetown University in 1978, and M.D. from Johns Hopkins University, in 1982. [7] [8] At the University of California, San Francisco, he completed a fellowship on Hematology-Oncology training where he began to work with the MYC gene. [9]

Career

In 1987, Dang returned to Johns Hopkins where he took a faculty position. He was Director of the Division of Hematology at Johns Hopkins Hospital from 1993-2003. [10] He also served as Johns Hopkins Family Professor in Oncology Research. As of 2002, he became Vice Dean for Research, [11] and Director of the Johns Hopkins Institute for Cell Engineering. [12] [7]

From 2002 to 2003, Dang was the President of the American Society for Clinical Investigation. [2] In his 2003 presidential address, he remarked, "I wish to remind all of us of the power of healing. Be it in the laboratory, at the cageside, bedside or computerside, we, as physicians, all have the ability to heal." [13]

As of September 1, 2011, Dang became the John H. Glick Professor of Medicine [14] and the Director of the Abramson Cancer Center at the University of Pennsylvania. [11]

As of July 1, 2017, Dang became the Scientific Director of the Ludwig Institute for Cancer Research, with the responsibility of overseeing the Institute's scientific strategy for studying the prevention, diagnosis, and treatment of cancer. [12] The Ludwig Institute has branches in the United States, Switzerland, and the United Kingdom. [7] He was also appointed a professor at the Wistar Institute on the campus of the University of Pennsylvania, which hosts the Ludwig Laboratory during his tenure as The Ludwig Institute's Scientific Director. [15] [16]

In 2018, Dang became Editor-in-Chief of Cancer Research , a peer-reviewed scientific journal published by the American Association for Cancer Research. He published his first editorial in January. [17] [18]

Research

Dang's research has focused on cancer cells and genetics, notably on energy utilization of cancer cells. [7] Research Dang's laboratories has contributed to the understanding of the function of the MYC a gene associated with different cancers. [7] [19] Dang has examined the mechanisms and molecular signaling pathways governing the metabolism of cancer. By first establishing the mechanistic link between MYC and cellular energy metabolism, he identified the MYC gene as a master regulator of cell proliferation and cellular metabolism. This research has contributed to the idea that genetic alterations re-program the energy utilization of tumors and specialize cancer cells to rely on specific fuel sources. [19] [7] [4] This work may help to explain the Warburg effect. Disrupting communication signalling pathways in cancer cells is a possible strategy for the development of drugs to battle cancer. [20] [21]

Eric Fearon conducted his postdoctoral research in Dang's laboratory, where he developed a system for the study of protein-protein interactions in living mammalian cells. [22]

Dang is also a proponent of chronotherapy, the idea that the delivery of drugs can be timed to take advantage of the body’s natural 24-hour rhythms, to minimize side effects and maximize treatment effectiveness. The National Cancer Institute has begun to support research into the function and regulation of clock genes and interactions between circadian rhythms, diseases, and treatments. [1] [23] [24]

Awards

Related Research Articles

<span class="mw-page-title-main">Stanley Plotkin</span> American physician

Stanley Alan Plotkin is an American physician who works as a consultant to vaccine manufacturers, such as Sanofi Pasteur, as well as biotechnology firms, non-profits and governments. In the 1960s, he played a pivotal role in discovery of a vaccine against rubella virus while working at Wistar Institute in Philadelphia. Plotkin was a member of Wistar’s active research faculty from 1960 to 1991. Today, in addition to his emeritus appointment at Wistar, he is emeritus professor of Pediatrics at the University of Pennsylvania. His book, Vaccines, is the standard reference on the subject. He is an editor with Clinical and Vaccine Immunology, which is published by the American Society for Microbiology in Washington, D.C.

<span class="mw-page-title-main">Perelman School of Medicine at the University of Pennsylvania</span> Medical school in Philadelphia, Pennsylvania, US

The Perelman School of Medicine, commonly known as Penn Med, is the medical school of the University of Pennsylvania, a private research university in Philadelphia, Pennsylvania. Founded in 1765, the Perelman School of Medicine is the oldest medical school in the United States and one of the seven Ivy League medical schools.

<span class="mw-page-title-main">Charles Sawyers</span> American physician-scientist (born 1959)

Charles L. Sawyers is a Howard Hughes Medical Institute (HHMI) investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK). HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries.

Otis Webb Brawley is an American physician and the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. He served as Chief Medical and Scientific Officer and Executive Vice President of the American Cancer Society from July 2007 to November 2018. He is board certified in internal medicine and medical oncology and is a Master of the American College of Physicians, Fellow of the American Society of Clinical Oncology, and a Fellow of the American College of Epidemiology. He is a member of the Institute of Medicine now known as the National Academy of Medicine.

<span class="mw-page-title-main">James P. Allison</span> American immunologist and Nobel laureate (born 1948)

James Patrick Allison is an American immunologist and Nobel laureate who holds the position of professor and chair of immunology and executive director of immunotherapy platform at the MD Anderson Cancer Center at the University of Texas.

Waun Ki Hong was Professor of Medicine at The University of Texas MD Anderson Cancer Center, where he served as chairman of the Department of Thoracic/Head & Neck Medical Oncology from 1993 to 2005 and as head of the Division of Cancer Medicine from 2001 to 2014. He was also an American Cancer Society Professor and the Samsung Distinguished University Chair in Cancer Medicine emeritus.

<span class="mw-page-title-main">William Kaelin Jr.</span> American Nobel Laureate, Professor of Medicine at Harvard University

William G. Kaelin Jr. is an American Nobel laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana–Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016, Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.

Webster K. "Web" Cavenee is the Director of Strategic Alliances in Central Nervous System Cancers at the Ludwig Institute for Cancer Research and Distinguished Professor at the University of California, San Diego. He was the Director of the Ludwig Institute for Cancer Research until 2015 when it was taken over by Richard Kolodner. His laboratory studies gene mutations in cancer, most notably in EGFR and glioblastoma multiforme.

<span class="mw-page-title-main">Carl H. June</span> American immunologist and oncologist

Carl H. June is an American immunologist and oncologist. He is currently the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania. He is most well known for his research on T cell therapies for the treatment of several forms of cancers. In 2020 he was elected to the American Philosophical Society.

Nancy E. Davidson is the executive director and president of Seattle Cancer Care Alliance, senior vice president, director of clinical oncology at Fred Hutchinson Cancer Research Center and head of the Division of Medical Oncology at the University of Washington School of Medicine. She focuses her research on breast cancer treatments and the genes that are mutated in various forms of breast cancer. She was president of American Association for Cancer Research from 2015 to 2016 and president of American Society of Clinical Oncology from 2007 to 2008.

<span class="mw-page-title-main">Daniel Von Hoff</span>

Daniel D. Von Hoff is the physician in chief and director of translational research at Translational Genomics Research Institute (TGen), and current Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute. He is also a professor of medicine at the Mayo Clinic and medical director of research as well as chief scientific officer at US Oncology. He is most notable for his work in targeted therapies for the treatment of cancer. He led the development of gemcitabine, and has several drugs in development.

<span class="mw-page-title-main">Elizabeth Jaffee</span> American oncologist

Elizabeth M. Jaffee is an American oncologist specializing in pancreatic cancer and immunotherapy.

Michael B. Kastan is the executive director of the Duke Cancer Institute and professor of pharmacology and cancer biology.

Joseph Rocco Bertino was an American researcher in the cancer pharmacology program at Rutgers Cancer Institute of New Jersey and professor of medicine and pharmacology at the Robert Wood Johnson Medical School in New Jersey. His research focused on the treatment of lymphoma.

Kornelia Polyak is a professor of medicine at Harvard Medical School and an internationally recognized breast cancer expert.

<span class="mw-page-title-main">Crystal Mackall</span> American physician and immunologist

Crystal L. Mackall is an American physician and immunologist. She is currently the Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine at Stanford University. She is the founding director of the Stanford Center for Cancer Cell Therapy.

Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.

James R. Downing is an American clinical executive. He is the president and chief executive officer of St. Jude Children's Research Hospital.

Maura Lianne Gillison is an American medical oncologist and molecular epidemiologist. She is credited as the first investigator to establish a connection between HPV and oral cancer.

Eric Reese Fearon is an American oncologist. He is the Emanuel N. Maisel Professor of Oncology at the University of Michigan and director of the University of Michigan Rogel Cancer Center.

References

  1. 1 2 3 Dolgin, Elie (1 May 2018). "How to ruin cancer's day". Knowable Magazine. doi: 10.1146/knowable-050118-014201 . Retrieved 8 August 2022.
  2. 1 2 3 4 5 6 7 "Chi Van Dang, MD, PhD". The American Society for Clinical Investigation. Retrieved November 13, 2021.
  3. 1 2 "Ludwig Cancer Research". April 4, 2018. Retrieved 9 August 2022.
  4. 1 2 3 "Chi Van Dang". American Academy of Arts & Sciences. November 11, 2021. Retrieved November 13, 2021.
  5. 1 2 3 "Chi Van Dang, MD, PhD". American Association for Cancer Research (AACR). Retrieved 9 August 2022.
  6. ↑ "Monographs Editor: Chi Van Dang". Genes & Cancer. 1 (6): 525. 1 June 2010. doi:10.1177/1947601910378525. ISSN   1947-6019. PMC   3092226 . PMID   21779456.
  7. 1 2 3 4 5 6 7 8 "Ludwig Cancer Research". Ludwig Cancer Research. Retrieved November 13, 2021.
  8. ↑ "Chi Van Dang - Faculty - About Us - Perelman School of Medicine at the University of Pennsylvania". Perelman School of Medicine. Retrieved November 13, 2021.
  9. ↑ "Chi Van Dang, M.D., Ph.D." The Wistar Institute. July 27, 2018. Archived from the original on December 1, 2020. Retrieved November 13, 2021.
  10. ↑ "Professor Văn-Chí Đặng". VinFuture Prize Foundation. Retrieved 9 August 2022.
  11. 1 2 Perelman School of Medicine at the University of Pennsylvania (27 June 2011). "Cancer Genetics Expert Chi Van Dang to Lead Penn Medicine's Abramson Cancer Center". News Wise. Retrieved 9 August 2022.
  12. 1 2 "AACR Congratulates Dr. Chi Van Dang on His Appointment as Scientific Director of the Ludwig Institute for Cancer Research | PressReleasePoint". Press Release Point. American Association for Cancer Research. December 22, 2016. Retrieved 9 August 2022.
  13. ↑ Dang, Chi Van (2004). "Celebrating the physician-scientist". Cancer Research. The Journal of clinical investigation. S1 (2).
  14. 1 2 "Researchers Behind the Journals: Researcher Profile Chi Van Dang". aacrjournals.org. Retrieved 9 August 2022.
  15. ↑ "Chi Van Dang, MD, PhD, Appointed Professor at the Wistar Institute - The ASCO Post". The ASCO Post. August 25, 2017. Retrieved 9 August 2022.
  16. ↑ "Chi Van Dang, MD, PhD, appointed professor at The Wistar Institute". Healio. July 10, 2017. Retrieved November 13, 2021.
  17. ↑ Dang, Chi Van (December 1, 2017). "Convergence to Cure Cancer through Research: A Message from the New Editor-in-Chief". Cancer Research. American Association for Cancer Research (AACR). 78 (1): 3–4. doi: 10.1158/0008-5472.can-17-3771 . ISSN   0008-5472. PMID   29298804.
  18. ↑ "Chi Van Dang, MD, PhD Named Editor-in-Chief of Cancer Research - The ASCO Post". The ASCO Post. January 25, 2018. Retrieved 9 August 2022.
  19. 1 2 "Faculty - Abramson Family Cancer Research Institute". Perelman School of Medicine at the University of Pennsylvania. Retrieved November 13, 2021.
  20. ↑ Apple, Sam (12 May 2016). "An Old Idea, Revived: Starve Cancer to Death". The New York Times.
  21. ↑ Camarda, Roman; Williams, Jeremy; Goga, Andrei (2017). "In vivo Reprogramming of Cancer Metabolism by MYC". Frontiers in Cell and Developmental Biology. 5: 35. doi: 10.3389/fcell.2017.00035 . ISSN   2296-634X. PMC   5386977 . PMID   28443280.
  22. ↑ "Society of Scholars Inducts New Members". Johns Hopkins University. May 14, 2007. Retrieved June 27, 2021.
  23. ↑ Walton, Zandra E.; Altman, Brian J.; Brooks, Rebekah C.; Dang, Chi V. (4 March 2018). "Circadian Clock's Cancer Connections". Annual Review of Cancer Biology. 2 (1): 133–153. doi: 10.1146/annurev-cancerbio-030617-050216 . ISSN   2472-3428. S2CID   91120424 . Retrieved 9 August 2022.
  24. ↑ Kreier, Freda (22 June 2022). "These cancer cells wake up when people sleep". Nature. doi:10.1038/d41586-022-01724-w . Retrieved 9 August 2022.
  25. ↑ Wasta, Vanessa (June 8, 2012). "Cancer Genetics Expert Honored by Johns Hopkins Alumni Association - 06/08/2012". Johns Hopkins Medicine. Retrieved 9 August 2022.
  26. 1 2 Simpkins, Beth. "Three JHU Researchers Elected to Institute of Medicine". Johns Hopkins Medicine. Retrieved 9 August 2022.
  27. ↑ "Mark Brothers Lectures – Sept. 9, 2003" (PDF). Scope newsletter. Retrieved 9 August 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.